Skip to main content

Table 4 Incidence rates of infusion/injection reactions by bDMARD treatment

From: Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Outcomes Abatacept Other bDMARDs
Overall TNFi Non-TNFi bDMARDs
No. of events/ no. of patients IR (95% CI)* No. of events/ no. of patients IR (95% CI)* No. of events/ no. of patients IR (95% CI)* No. of events/ no. of patients IR (95% CI)*
Any infusion reaction 115/1330 5.36 (4.42, 6.43) 196/1336 9.25 (8.00, 10.64) 106/985 7.00 (5.73, 8.47) 74/501 9.38 (7.36, 11.77)
Severe infusion reactions 27/1330 1.26 (0.83, 1.83) 41/1336 1.94 (1.39, 2.63) 24/985 1.59 (1.02, 2.36) 12/501 1.52 (0.79, 2.66)
Any injection reaction 53/626 8.19 (6.13, 10.71) 573/1690 23.43 (21.55, 25.43) 550/1679 22.62 (20.76, 24.59) 3/20 12.46 (2.57, 36.41)
Severe injection reactions 3/626 0.46 (0.10, 1.35) 46/1690 1.88 (1.38, 2.51) 40/1679 1.65 (1.18, 2.24) 1/20 4.15 (0.11, 23.14)
Severe injection or infusion reactions 37/1496 1.57 (1.11, 2.17) 95/2648 2.31 (1.87, 2.82) 65/2361 1.85 (1.42, 2.35) 14/512 1.75 (0.95, 2.93)
  1. *Per 100 patient-years
  2. bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, IR incidence rate, TNFi tumour necrosis factor-α inhibitor
\